| abstract |
The present invention relates to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives having the structure of formula I as SSAO/VAP-1 inhibitors, as defined in the description. The present invention also relates to methods of using compounds of formula I, or pharmaceutically acceptable salts or derivatives thereof, for the treatment of various indications such as inflammatory diseases, eye diseases, fibrotic diseases, diabetes-induced diseases and cancer. |